View Press Releases
-
VERICHEM OFFERS CLINICAL REFERENCE MATERIALS FOR THE CALIBRATION VERIFICATION TESTING OF LACTATE ASSAYS
VERICHEM LABORATORIES now offers a liquid stable and ready-to-use set of clinical reference materials for use with the clinical testing of Lactate.
Sep 18, 2022
-
Step up Research on Magnetic Metal Complexes Using Versatile Materials
-
High-Quality Dexmedetomidine Hydrochloride (API) Meeting CP & EP Standards
-
Liposomes as Drug Delivery Vehicles
-
BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing
VivoSTART GMP-grade leukopaks complement BioIVT’s GMP-grade human AB serum, providing a complete solution for advanced therapy development.
Sep 19, 2022
-
Integrated DNA Technologies Expands Customization Options for Alt-R™ Custom CRISPR gRNA Libraries for Drug Discovery
-
Inizio Biotech makes key leadership appointment to meet demand from emerging biotech
-
Anti-inflammatory drug candidate DMXD-011 shows efficacy in ex-vivo human studies
-
TFDA Grants CTL Amedica License to Market MATISSE™ ACIF Cage System
The Taiwan Food and Drug Administration has granted CTL Amedica Corporation a license to market the MATISSE Anterior Cervical Interbody Fusion (ACIF) Cage System.
Sep 14, 2022
-
Clinion - Platinum Sponsor for ISCR 3rd Autumn Conference 2022
-
BrightInsight Selects Lyniate to Enhance Interoperability Strategic Engagement Will Improve Information Exchange for Regulated Digital Health Solutions Built on the BrightInsight® Platform
-
Graphene Modification Helps to Unlock New Potentials
-
Accelerated Shelf-Life Testing to Assess Drug Stability
-
Four Most Commonly Used Surfactants You Should Know
-
Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals
-
BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates
XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies.
Sep 11, 2022
-
Molecular Devices and HeartBeat.bio announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery
Molecular Devices and HeartBeat.bio AG have entered into a co-development agreement to commercialize a first-of-its-kind automated offering that will enable researchers to reliably scale production of Cardioids and advance cardiac drug discovery.
Sep 11, 2022
-
BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies.
Sep 11, 2022
-
Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022
-
DNAnexus Selected as Platform Provider of the Trusted Research Environment for UK’s Largest Health Research Program
DNAnexus awarded a 3-year contract by Our Future Health to provide a scalable, cloud-based trusted research environment for the large-scale population research program that aims to recruit up to 5 million volunteers. Approved researchers from the global life sciences, healthcare, and academic communities will be able to use the DNAnexus platform to securely explore and analyze the de-identified data.
Sep 11, 2022